updated 10/21/2004 9:42:15 AM ET 2004-10-21T13:42:15

Pharmaceutical giant Merck & Co. said Thursday that third-quarter earnings dropped significantly year-over-year on charges related to the withdrawal of Vioxx from the market.

Quarterly net income fell to $1.33 billion, or 60 cents per share, from $1.86 billion, or 82 cents per share, a year ago. The latest quarter includes a charge of $552.6 million, or 25 cents per share, related to the withdrawal of Merck's Vioxx drug. The charge covers estimated customer returns of product previously sold, write-offs of inventory held by Merck and costs to undertake the withdrawal of the product.

Worldwide sales were $5.5 billion for the quarter, including a $491.6 million loss related to the withdrawal of Vioxx, which had sales of $2.5 billion in 2003.

Analysts surveyed by Thomson First Call were looking for Merck to post earnings of 71 cents per share on sales of $5.93 billion.

Global sales of asthma drug Singulair reached $626 million in the third quarter, which was 2 percent higher than the third quarter of 2003. Sales of Merck's coxib, Arcoxia, reached $61 million in the third quarter. Global sales of osteoporosis drug Fosamax were strong, reaching $778 million during the quarter, representing year-over-year growth of 13 percent.

Merck anticipates fourth-quarter earnings per share of 48 cents to 53 cents, which includes the impact of $700 to $750 million in foregone Vioxx sales of VIOXX and potential additional fourth-quarter costs for the drug's withdrawal. As a result, Merck forecasts full-year 2004 profits of $2.59 to $2.64 per share, including Vioxx-related costs of 50 cents to 55 cents.

Analysts are predicting fourth-quarter and fiscal year earnings of 35 cents and $2.58 per share, excluding items.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com